CP-91149 treatment decreases muscle GP activity by converting the phosphorylated AMP-independent α form into the dephosphorylated AMP-dependent b form and inhibiting GP α activity and AMP-mediated GP b activation[1]. CP-91149 (10, 30, 50 μM) inhibits brain GP and causes glycogen accumulation in A549 cells[2]. Cell Viability Assay[1] Cell Line: Cells were transduced with adenoviruses and incubated in the presence of 25 mM glucose for 2 days. Concentration: 10 µM (glucose− or glucose+ for 18 h). Incubation Time: 3 h. Result: Promoted the conversion of GP a into GP b, according to α model proposed in hepatocytes. Western Blot Analysis[2] Cell Line: A549 cells. Concentration: 0, 10, 30, 50 μM. Incubation Time: 72 h. Result: A significant increase in glycogen accumulation was detected at 10 μM of CP-91149 as compared with untreated cells with a maximal glycogen accumulation at 30 μM. Intracellular glycogen content decreased at 50 μM CP-91149, perhaps explained by additional pharmacological effects of the drug. The dose-dependent accumulation of intracellular glycogen in A549 cells by CP-91149 indicates that CP-91149 inhibits brain GP in tissue culture.
Kinase Assay
Cell Assay
Animal Administration
References
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
